Overt and Mild Subclinical Hypothyroidism Do Not Influence Mean Platelet Volume in Premenopausal Women Having Low Cardiac Risk

Mean platelet volume (MPV) was studied in subclinical hypothyroidism (SH) and the results are conflicting. The aim of this study is to assess how MPV is affected in overt hypothyroidism (OH) and mild SH, the 2 end points of hypothyroidism, in patients having low cardiac risk. Premenopausal women without any cardiac risk, 18 with OH, 30 with mild SH, and 37 euthyroid controls were enrolled. Overt hypothyroidism group had higher low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels than the control group (P < .001 and P < .05, respectively). Increase in MPV was insignificant in OH group when compared with SH and control groups. No correlation was observed between MPV and metabolic and hormonal parameters. Both OH and SH did not influence MPV and high-sensitivity C-reactive protein (hs-CRP) in patients with low cardiovascular risk, but these findings need to be further evaluated in this patient group.

[1]  D. Ertuğrul,et al.  Mean platelet volume in patients with subclinical hypothyroidism , 2011, Platelets.

[2]  A. Artoni,et al.  Subclinical thyroid disease in elderly subjects. , 2010, Acta bio-medica : Atenei Parmensis.

[3]  Deepak L. Bhatt,et al.  Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[4]  B. Karagoz,et al.  The effect of subclinical hypothyroidism on platelet parameters , 2009, Hematology.

[5]  H. Völzke,et al.  The Association of Thyroid Dysfunction with All-Cause and Circulatory Mortality: Is There a Causal Relationship? , 2007 .

[6]  E. Coban,et al.  Platelet activation in subjects with subclinical hypothyroidism. , 2007, Medical Science Monitor.

[7]  E. Coban,et al.  The mean platelet volume in patients with obesity , 2005, International journal of clinical practice.

[8]  K. Huber,et al.  Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease , 2002, British journal of haematology.

[9]  C. Erem,et al.  Blood coagulation and fibrinolysis in patients with hyperthyroidism , 2002, Journal of endocrinological investigation.

[10]  N. Rifai,et al.  High Sensitivity C-reactive Protein: An Emerging Role in Cardiovascular Risk Assessment , 2002, Critical reviews in clinical laboratory sciences.

[11]  J. Loscalzo,et al.  Induction of platelet formation from megakaryocytoid cells by nitric oxide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Loo,et al.  6 Megakaryocytes and platelets in vascular disease , 1997 .

[13]  W. Halbmayer,et al.  Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease , 1995, Coronary artery disease.

[14]  J. Leonard,et al.  Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. , 1994, Blood.

[15]  W. Vainchenker,et al.  Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. , 1993, Blood.

[16]  M. Burr,et al.  Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.

[17]  V. Uscăţescu,et al.  Is interleukin-18 correlated with endothelial dysfunction and platelet activation in patients with unstable angina? , 2005, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[18]  J. Martin,et al.  Megakaryocytes and platelets in vascular disease. , 1997, Bailliere's clinical haematology.